JBS Science specializes in the development of innovative technologies for cancer screening and management through the analysis of circulating cell-free DNA (cfDNA) found in urine and blood. Their proprietary methods focus on creating sensitive quantitative PCR (qPCR) assays to detect tumor DNA markers, which can significantly enhance the noninvasive detection of primary and recurrent cancers. The company aims to revolutionize medical practices by providing personalized medicine solutions through liquid biopsy, thereby contributing to a reduction in global cancer mortality rates. Collaborations with leading biomarker researchers and clinical specialists further bolster their efforts to develop highly effective diagnostic and screening tools.

One of the key products offered by JBS Science is the Urine RT DNA Collection Kit, designed for at-home urine collection while preserving the stability of cfDNA for up to seven days. This kit includes components such as specimen collection cups and tubes pre-filled with a proprietary preservative, facilitating the safe transport of samples for analysis. JBS Science's research has demonstrated the presence of low molecular weight (LMW) urine DNA, which can contain tumor-derived DNA, making it a promising avenue for noninvasive genetic testing. Their ongoing research and development efforts are supported by various grants and awards, highlighting their commitment to advancing cancer diagnostics and improving patient outcomes.

United States

JBS Science is a biotechnology company that specializes in developing circulating cell-free DNA (cfDNA) in urine technology for improved cancer screening and management through liquid biopsy.

JBS Science

Company Details